Scout | Discovery and Development of Novel Therapeutics for Select Fungal Pathogens (R21/R33 Clinical Trial Not Allowed)

This opportunity is no longer accepting applications.

grant

Discovery and Development of Novel Therapeutics for Select Fungal Pathogens (R21/R33 Clinical Trial Not Allowed)

This grant supports early-stage research for developing new drugs to treat specific fungal infections caused by Candida auris, Aspergillus fumigatus, Coccidioides, and Mucorales. It uses a two-phase award system where progression to the second phase depends on achieving certain goals in the first phase.

Source

Agency: National Institutes of Health

Sub-agency: National Institute of Allergy and Infectious Diseases

Dates

Opportunity Released: September 23, 2024

Open for Submission: September 23, 2024

Submission Deadline: January 28, 2025

Application Window Closes: January 28, 2025

Keywords

drug discovery

translational research

fungal pathogens

novel therapeutics

Candida auris

Aspergillus fumigatus

Coccidioides

Mucorales

milestone-driven research

R21 R33 phase transition

Supporting Links

Documents

Similar Opportunities

Unlock similar opportunities

Get the full picture on this opportunity

Create a free Scout account to unlock everything you need to decide fast and win the grant.

Instant Fit Analysis

Let our grant expert AI score how well this opportunity aligns with your organization, strengths, gaps, and how to improve your chances of winning funding.
Deep agency & funder detail

Program context, sub-agency structure, and a full eligibility breakdown.
Source links & full documents

Jump straight to the solicitation and download every attachment.
Similar opportunities

Discover related funding matched to your work.

Get a Demo Sign Up

Already have an account? Sign In

Trusted by 500+ Happy Customers